Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

PLK4 inhibitor RP-1664

An orally bioavailable inhibitor of polo-like kinase 4 (PLK4), with potential antineoplastic activity. Upon oral administration, PLK4 inhibitor RP-1664 selectively inhibits PLK4, which results in the disruption of mitosis and the induction of apoptosis. This inhibits the proliferation of tumor cells that overexpress PLK4 and/or tripartite motif-containing protein 37 (TRIM37). PLK4, a member of the polo family of serine/threonine kinases overexpressed in a variety of cancer cell types, plays a crucial role in the regulation of centriole duplication during the cell cycle. Tumors with a high level of the E3 ubiquitin-protein ligase TRIM37 rely on PLK4 for survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:RP 1664
RP-1664
RP1664
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search